Oncology

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Health economic and outcomes research datasets have rarely been integral to product development and communication plans.

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

By

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

Roche invests in oncology start-up

Roche invests in oncology start-up

By

The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.

Five things for pharma marketers to know: Wednesday, December 30, 2015

Five things for pharma marketers to know: Wednesday, December 30, 2015

By

Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles

Baxalta's oncology chief builds out company's third leg

Baxalta's oncology chief builds out company's third leg

By

David Meek has been charged with building an oncology arm that matches the company's existing strengths in hematology and immunology.

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

By

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Monday, December 14, 2015

Five things for pharma marketers to know: Monday, December 14, 2015

By

Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug

Five things for pharma marketers to know: Wednesday, December 9, 2015

Five things for pharma marketers to know: Wednesday, December 9, 2015

By

Pfizer reveals Ibrance pricing strategy; AMA call for DTC ban may resonate due to pricing debate; Baxalta's Vonvendi receives FDA approval

AstraZeneca to use mobile app in cancer trials

AstraZeneca to use mobile app in cancer trials

By

AstraZeneca plans to incorporate a mobile app that gathers information about side effects in three clinical trials studying an experimental combination therapy for ovarian cancer.

Five things for pharma marketers to know: Wednesday, November 25, 2015

Five things for pharma marketers to know: Wednesday, November 25, 2015

By

FDA advisers vote against BioMarin's Duchenne drug; the FDA approves Lilly's lung-cancer drug; criticism mounts for Pfizer's proposed deal with Allergan

Five things for pharma marketers to know: Tuesday, November 24, 2015

Five things for pharma marketers to know: Tuesday, November 24, 2015

By

Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease

Five things for pharma marketers to know: Tuesday, November 17, 2015

Five things for pharma marketers to know: Tuesday, November 17, 2015

By

Addyi off to a slow start; Dr. Robert Califf faces Senate committee on FDA nomination; FDA grants Opdivo Breakthrough Therapy Designation in kidney cancer

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

By

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Bristol-Myers Squibb turns to DTC to promote Opdivo

Bristol-Myers Squibb turns to DTC to promote Opdivo

By

The campaign marks the drugmaker's foray into oncology DTC advertising as it vies for market share against competing treatment Keytruda.

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

By

Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.

Diagnostics at the center of lung-cancer drug clash

Diagnostics at the center of lung-cancer drug clash

By

Oncologist perception of diagnostics may grow as immuno-oncology treatments move toward first-line use, drugmaker execs say.

Opdivo expansion may displace Keytruda

Opdivo expansion may displace Keytruda

By

Bristol-Myers Squibb's Opdivo expanded indication in lung cancer could push Keytruda to the margins.

Six things for pharma marketers to know: Thursday, October 8, 2015

Six things for pharma marketers to know: Thursday, October 8, 2015

By

Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise

Keytruda's label confers edge for Opdivo

Keytruda's label confers edge for Opdivo

By

Keytruda scored an approval in lung cancer, but its narrow label will likely have it playing second fiddle.

Five things for pharma marketers to know: Monday, October 5, 2015

Five things for pharma marketers to know: Monday, October 5, 2015

By

Keytruda approved in non-small cell lung cancer; Enbrel biosimilar inches closer to approval; study finds no link between autism and vaccines

Five things for pharma marketers to know: Thursday, October 1, 2015

Five things for pharma marketers to know: Thursday, October 1, 2015

By

The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan's Juvederm receives marketing approval for lip augmentation

Five things for pharma marketers to know: Tuesday, September 22, 2015

Five things for pharma marketers to know: Tuesday, September 22, 2015

By

Report finds Americans overpay for cancer drugs; Clinton proposes end to pharma DTC as a tax write-off; Gilead HCV combo is effective across all strains of the virus

New data expected at lung-cancer conference on experimental drug combos

New data expected at lung-cancer conference on experimental drug combos

By

The conference will offer a glimpse at new data testing possible treatment strategies for combination therapies in the first-line setting.

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Five things for pharma marketers to know: Friday, August 14

Five things for pharma marketers to know: Friday, August 14

By

GSK studying Breo Ellipta in lung-cancer patients; researchers develop strains of yeast for painkillers in a lab; Wolters Kluwer acquires CME provider

Five things for pharma marketers to know: Monday, August 10

Five things for pharma marketers to know: Monday, August 10

By

CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration

Drugs that turn cancer into a chronic disease need new marketing strategies: report

Drugs that turn cancer into a chronic disease need new marketing strategies: report

By

Findings of a new report suggest ways pharma should rethink its commercial and R&D decisions in light of improved survival rates associated with some cancers.

Five things for pharma marketers to know: Tuesday, August 4

Five things for pharma marketers to know: Tuesday, August 4

By

Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014

Five things for pharma marketers to know: Monday, August 3

Five things for pharma marketers to know: Monday, August 3

By

Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

By

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Email Newsletters